To explore the differences in the green channel process of stroke in various regions of the same province, to target and shorten the time delay of emergency process, and to explore the key technologies of endovascular treatment of acute ischemic stroke. To investigate the use and embolectomy effect of Reco, the first embolectomy stent in China, in economically developed areas. Health economic assessment (cost-benefit analysis) of ischemic stroke patients in various regions of the province.

The Reco Embolectomy Stent is indicated for patients who cannot be treated with intravenous tissue activator (IVt-PA) or who have failed IVt-PA therapy and is intended to remove thrombus from a large intracranial vessel in patients with ischemic stroke to restore blood flow.

Inclusion Criteria:

• Patient age ≥18 years
• The clinical diagnosis was acute ischemic stroke
• Large vascular lesions were detected by head CT, CTA, MRI, MRA or DSA
• Preoperative baseline NIHSS score > 4
• MRS 0-1 before this stroke
• Mechanical thrombectomy was performed
• Use Reco thrombectomy bracket

Exclusion Criteria:

• epileptic seizure
• Sudden coma
• Neurological loss symptoms quickly improved
• Imaging was negative, but clinical symptoms did not rule out subarachnoid hemorrhage
• Previous intracranial hemorrhage, subarachnoid hemorrhage, and brain tumor (with mass effect)
• History of head trauma within 3 months prior to surgery
• History of arterial puncture with difficulty in compression and hemostasis within one week prior to surgery
• Physical examination revealed evidence of active bleeding or trauma (e.g. fracture)
• Women are known to be pregnant or breastfeeding
• Severe allergies to contrast agents are known

Patients undergoing endovascular treatment for acute ischemic stroke with the Reco Embolectomy Stent from December 2018 to June 2021.